Ivonescimab Stabilizes Advanced NSCLC Patient with Parkinson’s in China | Jiahui Cancer Center

SHANGHAI, March 7, 2026 – In a significant development for international cancer care, Jiahui International Cancer Center (JICC) in Shanghai has stabilized the condition of a U.S. Patient in his seventies battling advanced non-small cell lung cancer (NSCLC) complicated by Parkinson’s disease. The patient, who had exhausted standard treatment options in the United States, received a novel immunotherapy called ivonescimab, currently available only in China.

The case highlights a growing trend of patients seeking innovative cancer treatments abroad, and specifically, the potential of China’s emerging oncology breakthroughs. The patient had previously undergone care at MD Anderson Cancer Center, a leading U.S. Cancer institution, but had not responded to third- and fourth-line therapies. His physicians then recommended ivonescimab, a bispecific antibody designed to enhance the body’s immune response against tumors while simultaneously inhibiting tumor blood vessel growth.

How Ivonescimab Works: A Dual-Action Approach

Ivonescimab represents a new class of immunotherapy drugs. Traditional immunotherapies often focus on blocking PD-1, a protein that prevents the immune system from attacking cancer cells. However, tumors can develop resistance to these therapies. Ivonescimab takes a different approach by simultaneously targeting both PD-1 and VEGF (vascular endothelial growth factor). VEGF is crucial for the formation of new blood vessels that feed tumors. By inhibiting VEGF, ivonescimab aims to starve the tumor and make it more vulnerable to the immune system. This dual-action mechanism is intended to overcome resistance and improve treatment outcomes in solid tumors like NSCLC. The drug is described as the first approved PD-1/VEGF bispecific antibody for solid tumors.

Navigating International Care at Jiahui

The patient’s family connected with JICC after a video consultation arranged within a week of their initial inquiry. According to a statement released by Jiahui, the center’s responsiveness and organized approach were key factors in their decision. Jiahui International Cancer Center is partnered with Massachusetts General Hospital Cancer Center, facilitating streamlined international patient pathways, including remote consultations, travel coordination, and ongoing family communication. This support proved crucial when the patient experienced immune-related complications during treatment, requiring admission to the intensive care unit (ICU).

The JICC team rapidly coordinated care involving specialists in oncology, neurology, and critical care, as well as Dr. Zhou Caicun, the principal investigator of the ivonescimab clinical trials. The patient’s condition has since stabilized, and care is now focused on maintaining disease control.

Beyond the Individual Case: A Growing Trend

This case isn’t isolated. JICC is reporting a surge in inquiries and referrals from North America, Europe, Asia, and the Middle East, positioning Shanghai as a potential global hub for advanced cancer treatment. This trend reflects both the limitations of existing therapies for some cancers and the rapid pace of innovation in oncology, particularly in China. The availability of novel treatments like ivonescimab, which are not yet approved in the U.S. Or Europe, is a significant draw for patients who have exhausted conventional options. You can find more information about Jiahui International Cancer Center and their services at their website.

Challenges and Considerations in Medical Tourism

While medical tourism offers potential benefits, it’s not without its challenges. Patients traveling abroad for treatment face logistical hurdles, including travel arrangements, language barriers, and navigating different healthcare systems. Immune-related complications, as experienced by this patient, can be particularly complex to manage in a foreign environment. The long-term efficacy and safety of novel treatments like ivonescimab require ongoing monitoring and research. The PRNewswire report highlights the complexities of coordinating care across international borders.

The Patient’s Perspective

The patient’s daughter expressed profound gratitude for the care received at JICC, praising the dedication of the entire team, from doctors and nurses to support staff. She specifically acknowledged the attentive care provided by Ms. Cui, a caregiver who offered both medical attention and emotional support. “My father would especially like to express his heartfelt thanks to Ms. Cui, who has cared for him every day since his admission. Beyond her attentive bedside care, she has offered him encouragement, comfort, and hope,” she stated.

What’s Next: Ongoing Research and Global Access

The success of this case underscores the importance of continued research into novel immunotherapies and the potential for international collaboration in cancer care. Further studies are needed to confirm the efficacy and safety of ivonescimab in larger patient populations and to identify biomarkers that can predict which patients are most likely to benefit from this treatment. The drug’s developers will likely seek regulatory approval in other countries, potentially expanding access to this innovative therapy for patients worldwide. The Jiahui International Cancer Center is actively involved in clinical trials and research initiatives aimed at advancing cancer treatment. For inquiries about international patient services, JICC can be contacted at [email protected] or via WhatsApp at +852 4619 1904. A similar story was also reported by Third News, further validating the details of this case.